Taiwan Advance Bio-Pharmaceutical Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 52.75 million compared to TWD 64.52 million a year ago. Revenue was TWD 315.98 million compared to TWD 318.24 million a year ago.

Net loss was TWD 10.68 million compared to net income of TWD 3.17 million a year ago. Basic loss per share from continuing operations was TWD 0.12 compared to basic earnings per share from continuing operations of TWD 0.04 a year ago.